Δ-3-Tetrahydrocannabinol
| Clinical data | |
|---|---|
| Other names | Delta-3-THC, Δ3-THC, Δ6a(10a)-THC, EA-1477 |
| Drug class | Cannabinoid |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H30O2 |
| Molar mass | 314.469 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Δ3-Tetrahydrocannabinol (often abbreviated as delta-3-THC or Δ3-THC) is a synthetic isomer of tetrahydrocannabinol (THC) developed during the original research in the 1940s to develop synthetic routes to the natural products Δ8-THC and Δ9-THC found in the cannabis. While the normal trans configuration of THC is in this case flattened by the double bond, it still has two enantiomers as the 9-methyl group can exist in an (R) or (S) conformation. The (S) enantiomer has similar effects to Δ9-THC though with several times lower potency, while the (R) enantiomer is many times less active or inactive, depending on the assay used. It has been identified as a component of vaping liquid products.